Delta‐like ligand 4 inhibitor drug treatment induces pulmonary hypertension in cancer clinical trials
Delta-like ligand 4 (DLL-4) inhibitor drugs are an emerging cancer treatment. In clinical trials for solid organ malignancies, intravenous administration of monoclonal antibodies that inhibit DLL-4 is associated with development of pulmonary hypertension, in the absence of left ventricular dysfunction. Analysis of 13 clinical trials showed that pulmonary hypertension is a complication of DLL-4 inhibition.
Authors
- Jason X.‐J. Yuan (ORCID: https://orcid.org/0000-0002-0685-4862)
- Moises Hernandez (ORCID: https://orcid.org/0000-0002-7651-2673)
- Patricia A. Thistlethwaite (ORCID: https://orcid.org/0000-0002-1986-7304)
- Cristian Puerta (ORCID: https://orcid.org/0000-0002-0953-0150)
- Nolan M. Winicki (ORCID: https://orcid.org/0000-0002-0784-2679)
- Casandra E. Besse
Institutions
- University of Florida (US)
- University of California San Diego (US)
Publication Details
- Journal
- Pulmonary Circulation
- Published
- 2024-10-01
- DOI
- https://doi.org/10.1002/pul2.12450
- Primary Topic
- Pulmonary Hypertension Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Institutes of Health